NTRK1 and gastrointestinal stromal tumor: For this purpose, we cultivated the SW620 cells either in RPMI+FBS or HPLM+FBS and then exposed them to the receptor tyrosine kinase inhibitor sunitinib (Suten, SU11248), which is currently used as a cancer therapy against renal cell carcinoma and gastrointestinal stromal tumor [28,29].